Papers/PMID:31454777
Cholecalciferol in relapsing-remitting MS: A randomized clinical trial (CHOLINE).
Neurology(R) neuroimmunology & neuroinflammation2019The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
calciol — decreases expanded Disability Status Scale (EDSS)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Average progression of the EDSS score was significantly lower in the cholecalciferol group (−0.06 ± 0.78) compared with the placebo group (0.32 ± 0.87, 95% CI −0.614 to −0.043; p = 0.03).”
Quoted verbatim from Cholecalciferol in relapsing-remitting MS: A randomized clinical trial (CHOLINE).. - Study
- RCT
- Duration
- 22 months
- Dose
- 100,000 IU oral solution every other week (equivalent to 7,143 IU/day) for 96 weeks
- Population
- Completers' population only (patients who finished the 96-week trial, 45 per arm) with relapsing-remitting MS, low serum 25OHD, all on interferon beta-1a background in both arms; not the intention-to-treat population
Cholecalciferol in relapsing-remitting MS: A randomized clinical trial (CHOLINE).2019PMID:31454777An author is affiliated with a producerPermalink